Beranda › Mieloma Multipel › Distrik Columbia › Washington
Uji klinis Mieloma Multipel di Washington, DC
22 studi untuk Mieloma Multipel mencari peserta di lokasi sekitar Washington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Menerima pesertaFase 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Menerima pesertaFase 3
- Research Site, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Menerima pesertaStudi observasional
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Menerima pesertaFase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Tissue Collection for Studies of Lymph Cancer
Menerima pesertaStudi observasional
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Menerima pesertaFase 4
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi jauhnya
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Menerima pesertaFase 3
- Center for Cancer and Blood Disorders, Bethesda · 7 mi jauhnya
18F-Fluciclovine PET/CT in Multiple Myeloma
Menerima pesertaFase 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Menerima pesertaFase 3
- American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda · 7 mi jauhnya
A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma
Menerima pesertaFase 2
- Lombardi Comprehensive Cancer Center, Washington D.C.
Collection of Tissue Samples for Cancer Research
Menerima pesertaStudi observasional
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauhnya
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Menerima pesertaFase 3
- Georgetown University Medical Center, Washington D.C.
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Menerima pesertaFase 3
- MedStar Washington Hospital Center MedStar Georgetown Cancer Institute, Washington D.C.
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Menerima pesertaFase 2
- GSK Investigational Site, Bethesda · 7 mi jauhnya
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Menerima pesertaFase 3
- Sibley Memorial Hospital, Washington D.C.
Mosaic Trial for Stem Cell Transplant Recipients
Menerima peserta
- Georgetown University School of Medicine, Washington D.C.
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 1
- Maryland Oncology Hematology - Silver Spring /ID# 268562, Silver Spring · 7 mi jauhnya
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Menerima pesertaFase 1/2
- The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 mi jauhnya
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
Menerima pesertaFase 3
- Sibley Memorial Hospital, Washington D.C.
Cancer Experience Registry (CER) for Cancer Patients and Caregivers
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Cancer Support Community Research & Training Institute, Washington D.C.
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
Menerima pesertaFase 3
- GSK Investigational Site, Washington D.C.
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Menerima pesertaFase 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Uji klinis Mieloma Multipel di kota lain
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA42 studi
- Houston, TX38 studi
- Durham, NC37 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Edison, NJ22 studi
Studi lain di Washington
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil55 studi
- Kanker Payudara46 studi
- Kanker Metastatik43 studi
- Kanker Paru41 studi
- Kanker Prostat38 studi
- Obesitas33 studi
- Kanker Kolorektal29 studi
- Penyakit Kardiovaskular28 studi
- Kanker Kandung Kemih26 studi
- Leukemia Mieloid Akut24 studi
- Kanker Ovarium23 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.